However, CD4+ T cells from the tumor-bearing and anti-IL-6 treatment alone groups reduced the cytotoxicity of the corresponding CD8+ T cells (Figure 5C), which further demonstrated that CD4+ T cells from combination therapy could enhance the cytotoxic function of CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.